Physician profile
Surjit Kahlon
NPI 1790719623
$6,792.33
in general payments reported to CMS, 2019-2025
48 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2021: $260 · 2022: $708 · 2023: $1,674 · 2024: $1,507 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,062 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.45 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,177.43 | 2019-2025 | Nuplazid, Daybue |
| Abbvie INC. | $1,135.82 | 2022-2025 | |
| Ucb, INC. | $617.68 | 2023-2025 | Fintepla, Rystiggo, Briviact |
| Pfizer INC. | $384.62 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $264.02 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $198.82 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $194.08 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amneal Pharmaceuticals LLC | $187.43 | 2023-2025 | Crexont, Rytary |
| Mdd US Operations, LLC | $181.17 | 2019-2025 | |
| Biogen, INC. | $146.07 | 2021-2025 | Tysabri, Vumerity |
| Allergan, INC. | $138.46 | 2022 | |
| Abbott Laboratories | $137.50 | 2019 | |
| Jazz Pharmaceuticals INC. | $126.65 | 2022-2024 | |
| Gilead Sciences, INC. | $120.00 | 2019 | |
| Emd Serono, INC. | $114.35 | 2019-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surjit Kahlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.